Alkermes plc
ALKS
Rang in aandelen
#2637
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Aandeelprijs
$43.05
Marktkapitalisatie
$7.22B
Verandering (1 dag)
4.43%
Verandering (1 jaar)
42.25%
Land
IE
Handel Alkermes plc (ALKS)
Categorie
Healthcare
Aantal uitstaande aandelen voor Alkermes plc (ALKS)
Aantal uitstaande aandelen per June 2026: 166.61M
Volgens de laatste financiële rapporten en de aandelenkoers van Alkermes plc bedraagt het huidige aantal uitstaande aandelen 166.61M. Aan het einde van December 2023 had het bedrijf 166.22M uitstaande aandelen. Het aantal uitstaande aandelen wordt meestal beïnvloed door aandelensplitsingen en terugkoop van aandelen.
Geschiedenis van uitstaande aandelen van Alkermes plc (ALKS) van 2000 tot 2026
Uitstaande aandelen aan het einde van elk jaar
| Jaar | Uitstaande aandelen | Wijzigen |
|---|---|---|
| 2026 (TTM) | 166.61M | 0.74% |
| 2024 | 165.39M | -0.50% |
| 2023 | 166.22M | 1.52% |
| 2022 | 163.74M | 1.74% |
| 2021 | 160.94M | 1.35% |
| 2020 | 158.80M | 1.12% |
| 2019 | 157.05M | 1.25% |
| 2018 | 155.11M | 1.11% |
| 2017 | 153.42M | 1.27% |
| 2016 | 151.48M | 1.53% |
| 2015 | 149.21M | 2.71% |
| 2014 | 145.27M | 10.30% |
| 2013 | 131.71M | 0.00% |
| 2012 | 131.71M | 14.83% |
| 2011 | 114.70M | 19.97% |
| 2010 | 95.61M | 0.81% |
| 2009 | 94.84M | -0.34% |
| 2008 | 95.16M | -5.54% |
| 2007 | 100.74M | 1.51% |
| 2006 | 99.24M | 9.03% |
| 2005 | 91.02M | 1.03% |
| 2004 | 90.09M | 9.76% |
| 2003 | 82.08M | 27.52% |
| 2002 | 64.37M | 1.10% |
| 2001 | 63.67M | 14.21% |
| 2000 | 55.75M | 0.00% |
Uitstaande aandelen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Uitstaande aandelen | Verschil | Land |
|---|---|---|---|
| 253.90M | 52.39% |
US
|
|
| 396.00M | 137.68% |
US
|
|
| 478.91M | 187.44% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -62.68% |
NL
|
